



PROJECT MUSE®

Perceived Ability to Treat Opioid Use Disorder in West Virginia

A. Brianna Sheppard, Jonathan C. Young, Steve M. Davis, Garrett E. Moran

Journal of Appalachian Health, Volume 3, Issue 2, Spring 2021, (Article)

Published by The University Press of Kentucky



➔ For additional information about this article

<https://muse.jhu.edu/article/793225>



JOURNAL OF APPALACHIAN HEALTH
a healthy and thriving appalachia

Perceived Ability to Treat Opioid Use Disorder in West Virginia

A. Brianna Sheppard, PhD, MA
West Virginia University Institute for Community and Rural Health

Jonathan C. Young
West Virginia University Health Sciences Center Office of Health Affairs

Steve M. Davis, PhD
Department of Health Policy, Management, and Leadership
West Virginia University School of Public Health

Garrett E. Moran, PhD
Professor, Health Policy, Management, and Leadership
West Virginia University School of Public Health

Recommended Citation:

Sheppard AB, Young JC, Davis SM, Moran GE. Perceived Ability to Treat Opioid Use Disorder in West Virginia. J Appalach Health 2021;3(2):32–42. DOI: <https://doi.org/10.13023/jah.0302.04>

Copyright © 2021 A. Brianna Sheppard, Jonathan C. Young, Steve M. Davis, and Garrett E. Moran

ABSTRACT

Introduction: Medication-assisted treatment (MAT) is an evidence-based therapy for opioid use disorder (OUD) that has not been fully implemented in rural areas due to patient, provider, and logistical barriers. Limited information is available on provider perceptions of barriers to MAT in rural Central Appalachia which has very high rates of OUD compared to the rest the United States.

Purpose: Determine perceived barriers for potential prescribers to using MAT, including buprenorphine, as part of treatment for OUD in West Virginia.

Methods: A 30-question, anonymous survey was sent to physicians, physician assistants and advanced practice registered nurses using an online link. Link was distributed through the WV Medicaid provider list, professional association and institutional contact lists, and social media. Comparisons were made by provider waived or non-waived status.

Results: Overall, 84% of waived providers (n = 77) and only 8% of non-waived providers (n = 341) indicated ever prescribing a form of MAT for OUD; 73% percent of waived providers were currently prescribing MAT and accepting new patients with OUD. Only 4% of non-waived providers were currently prescribing MAT and 21% were currently accepting new patients with OUD. Lack of available mental health and psychosocial support services and concerns about diversion or misuse of medication were the top perceived barriers to implementing MAT programs.

Implications: Implementing strategies to improve access to behavioral health care including telehealth and apps, provider training and addressing stigma around OUD treatment were identified as priorities that would help increase providers' willingness to prescribe medications for OUD treatment.

Keywords: Appalachia, medication-assisted treatment, opioid use disorder, stigma, rural health, behavioral health

INTRODUCTION

Higher rates of occupational injuries and chronic pain coupled with declining economic opportunities and a flood of prescription opioids have fueled rising rates of opioid misuse, resulting in rates of opioid use disorder (OUD) in Central Appalachia that are much higher than other parts of the U.S.¹ West Virginia currently leads the nation in per capita opioid overdose deaths. Its rate of drug overdose deaths in 2016 (52 per 100,000) was more than 250% higher than the national rate (19.8 per 100,000).² Medication-assisted treatment (MAT) is an effective, evidence-based therapy for OUD that can reduce cravings and promote relapse prevention that has been associated with a reduction in opioid overdose deaths.³ A recent systematic review with meta-analysis observed a 76% reduction in mortality risk among individuals with opioid use disorder while receiving MAT from 16 studies (pooled crude mortality rate [CMR], 0.24 [95% CI, 0.20–0.28]). Individuals not receiving MAT were eight times more likely to die from overdose (RR 8.10, 95% CI, 4.48–14.66) compared to patients receiving treatment.⁴ Despite this demonstrated efficacy, barriers remain to implementation in rural practices. Commonly reported barriers by rural providers include lack of knowledge about MAT; lack of specialty backup; concerns over drug diversion if medications are prescribed; insufficient provider staff time, reimbursement, resource availability including behavioral health, and stigma.^{5,6}

Efforts are currently underway in West Virginia (WV) to expand buprenorphine treatment via a hub-and-spoke model.⁷ Under a hub-and-spoke model, smaller hospitals and clinics (i.e., spokes) are connected with larger organizations with specialty care (i.e., hubs) to increase local provider education and facilitate local treatment capacity and transfers to specialty care when indicated.⁸ This model has been found to be particularly helpful in the rural setting where declining employment opportunities and other resource strains have led to small hospital and clinic closures.⁸ In particular, the hub and spoke system may overcome the previously observed MAT implementation barriers in rural settings, especially provider lack of knowledge and specialty backup.⁸ However, there is no previously published information regarding perceived MAT prescribing barriers reported by providers in WV, which has the highest opioid overdose death rate in the nation.⁹ A cross-sectional survey of WV providers was conducted to elucidate perceived barriers to implementing MAT programs that may inform policy and other structural interventions to promote diffusion of this life-saving, evidence-based treatment (see Additional Files).

METHODS

Participants and Procedures

A cross-sectional study using total population sampling was conducted using an online survey link and recruitment script. The survey link embedded within the recruitment script was sent to the email on file to a total of 20,762 individuals on the WV Medicaid provider list at the time of the study. This list included physicians (N=15,667), physician assistants (N=1833) and advanced practice registered nurses (N=3262). Additional requests to complete the survey using the link sent to the e-mail address on file with WV Medicaid were through professional association and institutional contact lists, and social media.

Participants completed an anonymous 30-item survey adapted from a national study⁶ concerning the ability to use MAT as part of OUD treatment, hosted through Qualtrics (Provo UT). Data were collected between April 2019 and July 2019. MAT was defined as buprenorphine, methadone, naloxone, and injectable naltrexone except where exclusively stated otherwise in the survey. Forced choice, ranking, and open-ended questions were used. The West Virginia University Institutional Review Board acknowledged the study as exempt.

Data Analysis

Results are presented using descriptive statistics. Data regarding barriers to providing MAT as part of OUD treatment were collected on an ordinal scale and independent samples Mann-Whitney U tests ($\alpha=0.05$) with Bonferroni corrections to account for multiple comparisons were used to evaluate differences in mean ranks as a function of provider waiver status using SPSS v26. Note that physicians, nurse practitioners, and physician assistants must obtain a waiver from the Drug Enforcement Administration to allow them to prescribe buprenorphine for the treatment of opioid use disorder.¹⁰ Qualitative analysis of the responses to open-ended questions were reviewed by each member of the research team and consensus was reached on major themes emerging from the data.

RESULTS

The survey received 780 clicks and the final sample size, based on those who accessed the survey, was 431 respondents who completed at least one question on the survey (55.3%). A total of 303 respondents completed the entire survey (38.8%). Respondents' age ranged from 25 to 77 years (mean=49 years, n=194).

Sample characteristics are summarized in Table 1. The number of responses to each individual question are provided in Tables 1 and 2.

Table 1. Sample Characteristics

	N of respondents for each question type	% of respondents for question
ZIP Code	259	
West Virginia ZIP code	239	92
Gender	264	
Female	144	55
Male	120	46
Provided clinical practice type	317	
Rural health clinic	31	10.
Hospital-sponsored clinic	60	19
Community health clinic or federally qualified health center	42	13
Private practice	53	17
Veterans Affairs facility	4	1
Behavioral health facility	24	8
Emergency department	25	8
Inpatient hospital	25	8
Substance use treatment facility	12	4
Other type of facility	41	13
Type of Reimbursement for MAT (select all that apply)	203	
Private insurance	149	73
Medicare	147	72
Medicaid	154	76
Self-pay	148	73
WV Public Employees Insurance Agency	139	69

Major themes that emerged from open comments on reasons providers chose to offer MAT in their clinics they listed better outcomes, number of patients presenting with the problem, lack of providers for pregnant women, patient request, effectiveness, and starting practice in a clinic already providing MAT. Open comments indicated that stigma towards individuals with an OUD and providers who use medication to treat OUD, administrative burden, diversion, and lack of training/comfort in prescribing were perceived barriers to implementing MAT programs. Table 2 illustrates capacity and willingness to prescribe MAT as part of OUD treatment. Providers were most likely to accept patients on their current panel for MAT (n=85), followed by patients in their community not in their practice (n=75), patients of other clinicians in their clinic

(n=59) and patients outside their community (n=51). Two questions adapted from published literature¹¹ that assessed implicit bias related to treatment of substance use disorder were also included in the survey (see Supplemental Materials) as an additional measure of stigma towards individuals that misuse substances. Respondents reacted more positively to increasing general mental health funding (61%; n=115) versus specific funding for OUD treatment (45%; n=397).

Table 2. Capacity and Willingness to Prescribe MAT

Survey Item	Total # of responses	Yes		No	
		n	% Total	n	% Total
Have you taken the mandatory training to allow you to apply for a DEA waiver to prescribe buprenorphine?	428	98	23	330	77
If yes to completing the training, have you received a DEA waiver to allow you to prescribe buprenorphine?	102	77	75	25	25
Have you ever prescribed any form of MAT (buprenorphine, methadone, or naltrexone/Vivitrol) for treatment of OUD?	431	95	22	336	78
Do you currently prescribe MAT for treatment of OUD as part of your practice?	430	69	16	361	84
If no to having a waiver: If free training is made available and you were compensated for your time, would you be willing to obtain your DEA waiver to prescribe buprenorphine?	327	183	56	144	44
Are you currently accepting new patients with OUD?	330	106	32	224	68
Do you feel reimbursement should be increased for treatment of OUD?	397	179	45	218	55
Do you feel reimbursement should be increased for treating mental illness?	115	70	61	45	39

Mean rank was higher for non-waivered providers compared to those with waivers on all perceived barriers to incorporating MAT into treatment of OUD except financial/reimbursement concerns. Lack of available mental health or psychosocial support services and concerns about diversion or misuse of medication were ranked as first and second for all providers, in opposite order for non-waivered and waived providers, respectively. Statistically significant differences in mean ranks of perceived barriers dependent upon waiver status included: lack of available mental health or psychosocial support services,

concerns about diversion or misuse of medication, concerns about legal liability, lack of specialty backup for complex problems, concerns about attracting drug users to practice, outside scope of practice, lack of confidence in ability to manage patients with OUD, and lack of patient need (Table 3).

Table 3. Mean Ranking of Barriers to Implementing MAT

WAIVERED			Likert Scale: 1–Not a concern 2–Minor concern 3–Serious concern 4–Very serious concern	NOT WAIVERED			Mann-Whitney		
N = 77				N = 319*			Bonferroni Correction α=0.003		
n	Rank	Mean	Barrier	n	Rank	Mean	N	U	p
70	2	2.51	Lack of available mental health or psychosocial support services	252	1	3.16	322	6100	<0.0001
70	1	2.52	Concerns about diversion or misuse of medication	253	2	2.96	323	6782	0.002
69	5	2.29	Concerns about legal liability	254	3	2.82	323	6437	0.0004
69	6	2.24	Lack of specialty backup for complex problems	253	4	2.71	322	6467	0.0001
68	3	2.42	Time constraints	254	6	2.54	322	8146	0.455
70	11	1.84	Concerns about attracting drug users to your practice	253	7	2.51	323	6112	<0.0001
70	13	1.45	Outside my scope of practice	258	5	2.60	328	4042	<0.0001
70	14	1.41	Lack of confidence in my ability to manage patients with OUD	254	8	2.38	324	4313	<0.0001
70	8	2.01	Concerns with DEA intrusion on your practice	251	9	2.18	321	8338	0.495
70	4	2.39	Financial/reimbursement concerns	253	12	1.99	323	10713	0.005
70	10	1.88	Resistance from practice partners	253	10	2.06	323	8232	0.342
69	12	1.72	Resistance from practice administration	250	11	2.03	319	7557	0.094
70	7	2.07	Resistance from community	253	13	1.93	323	9705	0.193
50	9	1.98	Other	126	14	1.86	176	3181	0.907
68	15	1.31	Lack of patient need	254	15	1.67	322	6915	0.0026

*Reflects the number of respondents out of 330 total respondents indicating they had not completed the mandatory training to allow for application for a DEA waiver to prescribe buprenorphine that provided a response to questions identifying barriers.
Individual ns indicate the number of providers that responded “Yes” to each barrier listed.

IMPLICATIONS

The study goal was to identify the perceived barriers, willingness, and ability to treat OUD in WV, and identify potential targets for policy and procedural changes to support MAT as part of OUD treatment. Only 18% of respondents had completed the training requirements and received their waiver to prescribe buprenorphine as part of OUD treatment. More than half of those who did not currently have a waiver to prescribe buprenorphine indicated a willingness to complete the requirements if free training and compensation were provided. More than 80% of waived providers indicated they had ever prescribed an OUD MAT drug, higher than the national average of 58%.¹² Patient need was identified as a reason for prescribing MAT in open-ended comments and ranked lowest on perceived barriers. Results indicate most respondents are currently or are at least willing to incorporate MAT into their practice to address the opioid epidemic in WV.

Lack of available mental health or psychosocial support services and drug misuse/diversion were the two most serious concerns for both waived and non-waived providers, the same top barriers identified in the national study from which the current survey was adapted⁶ as well as a similar study of rural primary care providers⁵. Forty-eight of WV's 55 counties are considered Mental Health Professional Shortage Areas¹³ and a statewide behavioral health workforce learning collaborative was established in 2019 to inform policies and practices addressing this workforce shortage. Work is also underway in WV to expand the use of telehealth and phone-based apps that can support treatment in rural areas with few providers and offer more immediate access to services, including behavioral health. Misuse of diverted buprenorphine is most often done to manage withdrawal symptoms and avoid risk associated with use of street drugs.^{14,15} Training on how to identify withdrawal symptoms and adjust dosing accordingly may reduce risk of misuse, abuse, and diversion. A 2016 survey of experienced rural buprenorphine prescribers identified recommendations to avoid problems with the DEA: *all physicians recommended that providers follow all DEA rules strictly (available on the DEA and SAMHSA websites),¹⁶ keep detailed records, and be prepared for the DEA to visit. Physicians who reported strictly following these rules did not report being concerned about the DEA.*¹⁷

It is noteworthy that five of the top six concerns were identical for those providers who already held the waiver to prescribe buprenorphine and those who had not yet received the waiver. While there were statistically significant differences

between their ratings, as well as differences in rank order, most of the concerns were shared. The very practical concern for financial/payment issues was ranked fourth by those currently waived but ranked twelfth for those not without a waiver.

Results indicated stigma around provision of MAT for treating OUD. Respondents were more likely to agree reimbursement should be increased for mental health more generally than for OUD specifically, consistent with previous studies exploring implicit bias.¹¹ Resistance from practice partners, administration and community were ranked as minor concerns; however, stigma was indicated in open-ended comments such as: *suboxone is a drug of abuse, I strongly believe there should be a better way, substitutes one addiction for another* as well as *attracting drug users to practice*. The latter comment seemed to be a more serious concern for non-waivered providers.

Medication-assisted treatment expansion efforts are being implemented across the state and preliminary findings indicate an increased capacity to address the substance use disorder (SUD)/OUD epidemic, including buprenorphine as part of treatment.⁷ WV's modified hub and spoke model and Project ECHO provide platforms that can be leveraged to address perceived barriers such as legal liability, incorporating SUD/OUD treatment into scope of practice, increasing confidence in patient management, and addressing stigma.

The WV State Substance Use Response Plan goals for 2020–2022 include increasing the number of providers obtaining waivers by 20% each year, training current and future health care providers on evidence-based approaches to treatment and increasing the number of in-state clinical providers to meet needs of residents seeking SUD treatment.¹⁸ Data on perceived barriers from the current study can inform priorities and activities at state and regional levels to increase access to SUD treatment.

Limitations include a low response rate and small sample size compared to the number of potential prescribers in WV, limiting generalizability of findings. Two percent of the total population targeted by the survey email responded. Conclusions regarding implicit bias are limited due to the large difference in number of respondents for each question, potential confounds with question order, and less stigmatizing language used in the current study (opioid use disorder) compared to previously published work that used “addiction.”¹¹

SUMMARY BOX

What is already known on this topic?

Medication-assisted treatment (MAT) is an evidence-based therapy for opioid use disorder that has not been fully implemented in rural areas due to patient, provider, and logistical barriers.

What is added by this report?

The current study identified perceived barriers of potential prescribers to use MAT including buprenorphine as part of treatment for OUD in West Virginia, a mostly rural state entirely within Appalachia.

What are the implications for future research?

These findings can inform efforts to increase access to SUD treatment in the Appalachian region by prioritizing, implementing, and evaluating activities that address providers' perceived barriers to implementing MAT as part of OUD treatment.

REFERENCES

1. Moody L, Satterwhite E, Bickel WK. Substance use in rural central Appalachia: current status and treatment considerations. *Rural Ment Health* 2017; 41(2): 123–35. Doi: 10.1037/rmh0000064
2. Warfield S, Pollini R, Stokes CM, Bossarte R. Opioid-related outcomes in West Virginia, 2008–2016. *Am J Public Health* 2019; 109(2): 303–5. Doi: 10.2105/AJPH.2018.304845.
3. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. *Cochrane Database Syst Rev* 2016; 9(5):CD011117. Doi: 10.1002/14651858.CD011117.pub2.
4. Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ. Effects of medication-assisted treatment on mortality among opioid users: a systematic review and meta-analysis. *Mol Psychiatry* 2019; Dec 24(12): 1868–83. Doi: 10.1038/s41380-018-0095-5.
5. Andrilla CH, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. *Ann Fam Med* 2017; 15(4): 359–62. Doi: 10.1016/j.afm.2009.
6. Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. *Ann Fam Med* 2014; 12(2): 128–33. Doi: 10.1370/afm.1595.

7. Winstanely EL, Lander LR, Berry JH, et al. West Virginia's model of buprenorphine expansion: preliminary results. *J Subst Abuse Treat* Jan 2020; 108: 40–7. Doi: 10.1016/j.jsat.2019.05.005.
8. Elrod JK, Fortenberry JL Jr. The hub-and-spoke organization design revisited: a lifeline for rural hospitals. *BMC Health Serv Res*. 2017; 17(Suppl 4): 795. Doi: 10.1186/s12913-017-2755-5.
9. Merino R, Bowden N, Katemneni S, Coustasse A. The opioid epidemic in West Virginia. *Health Care Manag (Frederick)* 2019; 38(2): 187–95. Doi: 10.1097/HCM.0000000000000256.
10. Substance Abuse and Mental Health Services Administration. Become a buprenorphine waived practitioner. Available at: <https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner> Cited Feb. 23, 2021.
11. McGinty EE, Goldman HH, Pescosolido B, Barry CL. Portraying mental illness and drug addiction as treatable health conditions: effects of a randomized experiment on stigma and discrimination. *Soc Sci Med* Feb 2015; 126:73–85. Doi: 10.1016/j.socscimed.2014.12.010.
12. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. *J Addict Dis* 2006; 25(4): 91–103. Doi: 10.1300/J069v25n04_94.
13. Health Resources and Services Administration. HPSA Find website. <https://data.hrsa.gov/tools/shortage-area/hpsa-find>.
14. Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: motives for abuse, misuse and diversion. *J Subst Abuse Treat* Sept 2019;104:148–57. Doi: 10.1016/j.jsat.2019.07.005.
15. Lowfall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. *J Addict Med* Sept 2015;8(5):315–26. Doi: 10.1097/ADM.0000000000000045.
16. Substance Abuse and Mental Health Services Administration. Buprenorphine Practitioner Resources and Information. Available at: <https://www.samhsa.gov/medication-assisted-treatment/practitioner-resources> Published August 19, 2020. Accessed February 24, 2021.
17. Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. *J Rural Health* 2019;35(1), 113–21. Doi: 10.1111/jrh.12328.
18. West Virginia Department of Health and Human Resources, Office of Drug Control Policy. West Virginia Substance Use Response Plan. [https://dhhr.wv.gov/office-of-drug-control-policy/news/Documents/FINAL%20-%20West%20Virginia%202020_2022%20Council%20Substance%20Use%20Plan_January%2020,%202020%20\(as%20filed\).pdf](https://dhhr.wv.gov/office-of-drug-control-policy/news/Documents/FINAL%20-%20West%20Virginia%202020_2022%20Council%20Substance%20Use%20Plan_January%2020,%202020%20(as%20filed).pdf).

Ability to Treat Opioid Use Disorder in West Virginia

Block 1

Dear Participant,

This letter is a request for you to take part in a research project assessing barriers and facilitators to medication assisted treatment (MAT) for opioid use disorder in West Virginia. This survey is a joint effort of the WV Department of Health and Human Resources, Marshall Health, WV School of Osteopathic Medicine, and West Virginia University under the direction of Garrett Moran, PhD at WVU and Lyn O'Connell, PhD, at Marshall Health. Funding for the project was provided by the West Virginia Department of Health and Human Resources and the Substance Abuse and Mental Health Services Administration (SAMSHA). Your participation in this project is greatly appreciated and it will take no more than about 10 minutes to complete the attached questionnaire.

Your involvement in this project will be kept as confidential as legally possible. All data will be reported in the aggregate. Neither you nor your clinic will be identified when the results of this survey are reported. It will not be possible to link your contact information with individual survey results. You must be 18 years of age or older to participate. Your participation is completely voluntary. You may skip any question that you do not wish to answer and you may discontinue at any time. There is no penalty whether or not you decide to participate or to withdraw. West Virginia University's Institutional Review Board acknowledgement of this project is on file.

We hope that you will complete this brief questionnaire. The data gathered will help us understand and address factors that limit the availability of MAT for opioid use disorder in West Virginia. Should you have any questions about this letter or the project, please feel free to contact Brianna Sheppard, PhD, at 304-293-1444 or absheppard@hsc.wvu.edu.

Thank you for your time and help with this project.

Sincerely,

Garrett Moran, PhD

Lyn O'Connell, PhD

School of Public Health
Medicine
West Virginia University

Department of Family
Marshall University

Ability to Treat Opioid Use Disorder in West Virginia

Published research and clinical experience in West Virginia show that using evidence-based medication assisted treatment can successfully improve medical and social outcomes for as many as 50%-60% of patients with Opioid Use Disorder (OUD).

Medication-assisted treatment (MAT) most commonly includes three medications to treat OUD: Methadone (daily dosing of an opioid agonist); Naltrexone (opioid antagonist such as Vivitrol); or Buprenorphine (opioid agonist/antagonist such as Suboxone or Subutex) in combination with counseling and behavioral therapies.

MAT success rates are comparable to those for other chronic health conditions such as diabetes and hypertension. Providers treating patients with OUD report rapid and dramatic positive changes for patients upon entering treatment as well as high levels of personal reward in improving patients' lives.

The following survey, *Ability to Treat Opioid Use Disorder in West Virginia*, is designed to assess providers' availability and willingness to prescribe MAT to patients with OUD. Providers include physicians, physician assistants, and nurse practitioners.

Thank you very much for taking the time to complete and submit this survey. Your insight and information are very valuable to us.

Have you taken the mandatory training to allow you to apply for a DEA waiver to prescribe buprenorphine?

Yes

No

Have you received a DEA waiver to allow you to prescribe buprenorphine?

Yes

No

Have you ever prescribed any form of MAT (buprenorphine, methadone, or naltrexone/Vivitrol) for the treatment of OUD?

Yes

No

Do you currently prescribe MAT for treatment of OUD as part of your practice?

Yes

No

What made you decide to offer MAT at your clinic?

If free training is made available and you were compensated for your time, would you be willing to obtain your DEA waiver to prescribe buprenorphine?

Yes

No

Please indicate why you would choose not to obtain a waiver.

Please indicate whether or not each of the following are barriers to incorporating MAT into your practice for the treatment of OUD.

Very Serious
Concern

Serious
Concern

Minor Concern

Not a Concern

	Very Serious Concern	Serious Concern	Minor Concern	Not a Concern
Time constraints	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of patient need	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Financial/reimbursement concerns	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Resistance from practice partners	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Resistance from practice administration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Resistance from community	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Outside my scope of practice	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of specialty backup for complex problems	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of confidence in my ability to manage patients with OUD	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of available mental health or psychosocial support services	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Concerns about attracting drug users to your practice	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Concern about DEA intrusion on your practice	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Concerns about diversion or misuse of medication	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Concerns about legal liability	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you selected "Other", please describe other barriers to incorporating MAT into your practice for the treatment of OUD.

Do you feel reimbursement should be increased for treatment of OUD?

Yes

No

Do you feel reimbursement should be increased for treating mental illness?

Yes

No

Are you currently accepting new patients with OUD?

Yes

No

Approximately how many patients with OUD are you currently treating with MAT?

Not including yourself, how many providers are in your practice?

Not including yourself, how many providers in your clinic are currently waived by the DEA to prescribe buprenorphine?

Not including yourself, how many providers in your clinic are currently treating OUD with any form of MAT?

Please indicate which of the following groups of patients you accept for MAT.

- Patients who are already on my personal panel
- Patients of other clinicians in my clinic
- Patients from the community not in my practice
- Patients outside of my community

Which of the following best describes your clinical practice?

- Rural health clinic
- Hospital-sponsored clinic
- Community health clinic/FQHC
- Private practice
- Veterans Affairs facility
- Behavioral health facility
- Emergency department
- Inpatient hospital
- Substance use treatment facility
- Other

If you selected "Other", please describe your clinical practice setting.

Does your practice accept the following types of reimbursement for MAT?

	Yes	No
Private insurance	<input type="checkbox"/>	<input type="checkbox"/>
Medicare	<input type="checkbox"/>	<input type="checkbox"/>
Medicaid	<input type="checkbox"/>	<input type="checkbox"/>
Workers' compensation	<input type="checkbox"/>	<input type="checkbox"/>
Self-pay	<input type="checkbox"/>	<input type="checkbox"/>
PEIA	<input type="checkbox"/>	<input type="checkbox"/>

Are you aware and have you participated in any of the following Project ECHO Sessions? (Extension for Community Healthcare Outcomes)

	Aware	Participated
Chronic Pain	<input type="checkbox"/>	<input type="checkbox"/>
Medication-Assisted Treatment	<input type="checkbox"/>	<input type="checkbox"/>
HIV/Hepatitis C	<input type="checkbox"/>	<input type="checkbox"/>
Psychiatry	<input type="checkbox"/>	<input type="checkbox"/>

If you identify a patient who injects drugs and has not been tested for Hepatitis C, do you (please select all that apply)

Order a Hepatitis C test

Make a referral to another provider for Hepatitis C testing

Encourage the patient to get testing somewhere else e.g. Health Department

I do not really discuss testing

Not Applicable: I do not have any patients who inject drugs

How often to you talk about Hepatitis C screening and treatment with your patients who inject drugs (e.g. heroin, methamphetamine)

Never

Sometimes

Often

Always

Not Applicable: I do not have patients who use drugs

What year were you born?

What is your gender?

Male

Female

Prefer not to answer

What is your clinical specialty?

What is the zip of your principal practice?

Open Comments (confidential):

Powered by Qualtrics